Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Case description (72 yo female with palpitations)
- 72 yo female with palpitations: electrocardiogram
- 72 yo female with palpitations: echocardiogram
- Event monitor
- Atrial fibrillation - classification
- Why treat atrial fibrillation?
- Treatment goals and strategies
- Approach to treatment: anticoagulation
- Example: patient with AF not anticoagulated
- CHADS2 risk stratification
- CHA2S2-VASc risk stratification
- ASSERT trial
- Warfarin
- Warfarin anticoagulation in AF
- Warfarin – therapeutic range
- Time in therapeutic range (TTR)
- AFFIRM trial - gender differences
- HAS-BLED bleeding risk score
- Traditional anticoagulation
- Is home monitoring the answer?
- Other anticoagulants
- ACTIVE trial
- Anticoagulation for AF and bleeding
- RE-LY: dabigatran
- ROCKET AF: rivaroxaban
- AVERROES: apixaban
- ARISTOTLE: apixaban
- ACC/AHA guidelines
- Anticoagulation – the bottom line
- Anticoagulation – the future?
Topics Covered
- Atrial fibrillation: classification
- Treatment goals and strategies – Traditional and novel anticoagulation: data from clinical trials
Talk Citation
Olshansky, B. (2015, October 29). Atrial fibrillation - management, the challenge and new solutions 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/LMMS5175.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Brian Olshansky has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Atrial fibrillation - management, the challenge and new solutions 1
Published on October 29, 2015
35 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, I'm Dr. Brian Olshansky,
Professor of Medicine
at the University
of Iowa Hospitals
in Iowa City, Iowa.
Today, I would like to discuss
the management
of atrial fibrillation,
talk about some
of the challenges
and some of the new solutions.
But to do this, I would
like to focus on a patient,
a patient that you
may see in practice,
who has atrial fibrillation.
And I would just like to say
that atrial fibrillation
is becoming
a very large problem.
It is seen in virtually
any clinical practice now
and there are many
potential issues
with regard to
its management and treatment
and there are many solutions
that are also available.
And in some instances,
these solutions necessarily
do not work together
in a way that makes perfect
sense for all clinicians.
So this adds to
the challenges of the problem.
And I think this can
be well-highlighted
in the patient that I would
like to show you.
0:59
Here I describe a 72-year-old
female with palpitations.
Her chief compliant
is debilitating fatigue,
she has dyspnea
2-3 times a day,
mostly with exercise
and walking upstairs.
Her past medical
history is significant
for hypertension and diabetes
and she takes metoprolol,
25 milligrams twice a day.
And physical examination,
her blood pressure is 144/94,
and her pulse is
120 and irregular.
Her lungs are clear
and her heart is normal.
There is an irregular pulse
but no murmur or gallop.
And the rest of her physical
examination is unremarkable.
1:38
As you can see
on her electrocardiogram,
she has atrial fibrillation
with a narrow QRS complex
and no other specific
changes except the fact
that she has
an irregular rate and it's rapid
and she has perhaps
some evidence
for left ventricular
hypertrophy.